Supernus Pharmaceuticals (SUPN) Competitors $32.69 -0.13 (-0.40%) As of 12:09 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN vs. CORT, PRGO, PCRX, OMER, NKTR, ASMB, CPIX, LLY, JNJ, and ABBVShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Perrigo (PRGO), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). These companies are all part of the "pharmaceuticals" industry. Supernus Pharmaceuticals vs. Corcept Therapeutics Perrigo Pacira BioSciences Omeros Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Corcept Therapeutics (NASDAQ:CORT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings. Does the media refer more to CORT or SUPN? In the previous week, Corcept Therapeutics had 47 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 55 mentions for Corcept Therapeutics and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.88 beat Corcept Therapeutics' score of 0.50 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 22 Very Positive mention(s) 5 Positive mention(s) 15 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Supernus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CORT or SUPN more profitable? Corcept Therapeutics has a net margin of 22.35% compared to Supernus Pharmaceuticals' net margin of 9.16%. Corcept Therapeutics' return on equity of 24.54% beat Supernus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics22.35% 24.54% 20.24% Supernus Pharmaceuticals 9.16%7.79%5.67% Does the MarketBeat Community prefer CORT or SUPN? Corcept Therapeutics received 67 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.02% of users gave Supernus Pharmaceuticals an outperform vote while only 71.37% of users gave Corcept Therapeutics an outperform vote. CompanyUnderperformOutperformCorcept TherapeuticsOutperform Votes54671.37% Underperform Votes21928.63% Supernus PharmaceuticalsOutperform Votes47973.02% Underperform Votes17726.98% Which has more risk and volatility, CORT or SUPN? Corcept Therapeutics has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Do insiders & institutionals believe in CORT or SUPN? 93.6% of Corcept Therapeutics shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by insiders. Comparatively, 9.3% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, CORT or SUPN? Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$675.04M12.67$106.14M$1.2465.40Supernus Pharmaceuticals$661.82M2.73$1.32M$1.3224.55 Do analysts rate CORT or SUPN? Corcept Therapeutics presently has a consensus target price of $143.25, suggesting a potential upside of 76.66%. Supernus Pharmaceuticals has a consensus target price of $36.00, suggesting a potential upside of 11.11%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Supernus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryCorcept Therapeutics beats Supernus Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Remove Ads Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81B$6.78B$5.57B$7.51BDividend YieldN/A2.80%5.35%4.04%P/E Ratio30.286.9622.7918.09Price / Sales2.73197.25360.4985.80Price / Cash21.8365.6738.1634.64Price / Book1.925.926.483.98Net Income$1.32M$142.37M$3.20B$247.19M7 Day Performance-0.06%-9.21%-6.33%-6.02%1 Month Performance2.08%-10.14%-0.61%-7.10%1 Year Performance-4.28%-15.23%6.07%-4.12% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals2.9158 of 5 stars$32.69-0.4%$36.00+10.1%-1.1%$1.82B$661.82M30.55580Analyst UpgradeShort Interest ↓Gap DownCORTCorcept Therapeutics4.4011 of 5 stars$59.47+1.4%$99.75+67.7%+230.5%$6.27B$675.04M47.20300Analyst ForecastInsider TradeOptions VolumeAnalyst RevisionNews CoverageGap DownPRGOPerrigo4.8394 of 5 stars$27.73-0.7%$33.00+19.0%-10.9%$3.81B$4.37B-23.708,900Short Interest ↓News CoveragePositive NewsGap DownPCRXPacira BioSciences2.9708 of 5 stars$24.84+2.9%$27.22+9.6%-12.7%$1.15B$700.97M-12.24720OMEROmeros3.5984 of 5 stars$9.02-0.9%$22.50+149.4%+162.6%$522.71MN/A-3.90210Analyst ForecastNews CoverageGap DownNKTRNektar Therapeutics4.3657 of 5 stars$0.86-0.4%$4.92+471.3%-30.6%$160.16M$98.43M-1.02220Gap DownASMBAssembly Biosciences3.5631 of 5 stars$11.12+1.0%$35.00+214.7%-29.9%$70.68M$28.52M-1.65100CPIXCumberland Pharmaceuticals1.0616 of 5 stars$4.40-4.1%N/A+147.4%$61.46M$37.87M-5.7180LLYEli Lilly and Company4.9367 of 5 stars$865.94+3.4%$1,009.72+16.6%+7.3%$821.06B$45.04B73.9539,000JNJJohnson & Johnson4.3826 of 5 stars$163.43-0.1%$171.33+4.8%-1.5%$393.83B$88.82B24.58152,700Analyst ForecastGap UpABBVAbbVie4.5319 of 5 stars$209.25-0.4%$211.45+1.1%+13.4%$369.40B$56.33B87.1950,000Insider TradePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies CORT Alternatives PRGO Alternatives PCRX Alternatives OMER Alternatives NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SUPN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SUPN Stock Free SUPN Stock Alerts